Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, April 14, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited (“CK Hutchison”) shareholding in HUTCHMED remains unchanged, at 332,478,770 ordinary shares of par value US$0.10 each in the capital of HUTCHMED (“Shares”). Each American Depositary Share (“ADS”) represents five Shares. As announced on April 8, 2021, HUTCHMED issued a total of 16,393,445 Shares (equivalent to 3,278,689 ADSs) to funds affiliated with Baring Private Equity Asia. HUTCHMED was notified on April 14, 2021 that this issuance diluted CK Hutchison’s holding to 44.66 per cent of the total number of voting rights of HUTCHMED. The date on which the notification threshold was crossed was April 14, 2021.
 Held through CK Hutchison’s indirect wholly-owned subsidiary Hutchison Healthcare Holdings Limited.
HUTCHMED (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,200 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first two oncology drugs now approved and launched. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
|Mark Lee, Senior Vice President||+852 2121 8200|
|Annie Cheng, Vice President||+1 (973) 567 3786|
|Brad Miles, Solebury Trout||+1 (917) 570 7340 (Mobile) firstname.lastname@example.org|
|Ben Atwell / Alex Shaw, FTI Consulting||+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) HUTCHMED@fticonsulting.com|
|Joseph Chi Lo, Brunswick||+852 9850 5033 (Mobile)|
|Zhou Yi, Brunswick||+852 9783 6894 (Mobile) HUTCHMED@brunswickgroup.com|
|Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited||+44 (20) 7886 2500|